Compare ARK Genomic Revolution ETF (ARKG) vs KE Holdings Inc (BEKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs KE Holdings Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while KE Holdings Inc trades at $15.75 (market cap $17.21B). The key difference: KE Holdings Inc pays a 1.77% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, KE Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BEKE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $20.36 |
52-Week Low | $23.09 | $14.26 |
Market Cap | — | $17.21B |
Enterprise Value | — | $12.99B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BEKE trades at $15.57, up 2.1% today, with a bearish technical signal despite recent earnings beat. The company reported strong Q1 2026 results with EPS of $0.20 beating expectations of $0.14, driven by improved profitability despite lower revenue. Analyst consensus remains overwhelmingly bullish with 91.7% buy ratings, while technical indicators show oversold conditions suggesting potential reversal.
The outlook appears constructive given improving profitability and positive analyst sentiment, though risks include China's property market volatility and recent cash flow challenges. The stock's current valuation at P/E 35.6x reflects growth expectations, with potential upside if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
